Abstract: Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: Embodiments provided herein relate to systems for synthetically-engineered reciprocal chromosomal translocation for gene insertion into a population of organisms such as insects.

Abstract: Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substituent also conjugated to the polymer. The compounds/compositions demonstrate increased uptake across the blood brain barrier along with increased retention therein and retention within tumor. The compounds/compositions may also include improved synthesis scalability, improved purity, improved aqueous solubility, and a solid product or intermediate. The compounds/compositions may demonstrate improved antiangiogenic effect and improved efficacy against conditions, particularly cancers, requiring blood brain barrier permeability, for example, glioblastoma (GBM).

Abstract: Embodiments provided herein relate to systems for synthetically-engineered reciprocal chromosomal translocation for gene insertion into a population of organisms such as insects.

Abstract: Embodiments provided herein relate to systems for synthetically-engineered reciprocal chromosomal translocation for gene insertion into a population of organisms such as insects.

Abstract: Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.

Abstract: The present disclosure generally relates to methods and compositions for contraception. In some embodiments, vector based approaches for contraception are provided.

Abstract: Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.

Abstract: Embodiments provided herein relate to systems for synthetically-engineered reciprocal chromosomal translocation for gene insertion into a population of organisms such as insects.

Abstract: Described are compositions and methods for the induction of an antigen-specific tolerance in a vertebrate. Also described are compositions and methods for the induction of antigen-specific tolerance using a fusion or a complex of the antigen (e.g., an antibody or an enzyme) against which tolerance is desired with a phosphatidylserine-binding domain derived from a phosphatidylserine-binding protein (including peptides).

Abstract: The present technology generally relates to compositions, methods, and populations that allow for the regulation of insect population.

Abstract: Disclosed herein are components, systems and methods for regulating population of multicellular organisms, for example insects.

Abstract: The present disclosure generally relates to methods and compositions for contraception. In some embodiments, vector based approaches for contraception are provided.

Abstract: The invention pertains to pyrimidone compounds that serve as effective GSK-3 inhibitors. The invention further relates to pharmaceutical compositions and methods comprising such pyrimidone compounds; and the use of such compounds for treating certain disorders.

Abstract: Disclosed is a class of reagents for examining protein expression in vivo that does not require transfection, radiolabeling, or the prior choice of a candidate gene. Further, a series of puromycin conjugates was constructed bearing various labeling moieties. These conjugates were readily incorporated into expressed protein products in cell lysates in vitro and efficiently cross cell membranes to function in protein synthesis in vivo as indicated by flow cytometry, selective enrichment studies, and western analysis. The present invention demonstrates that labeled-puromycin conjugates offer a general means to examine protein expression in vivo.

Abstract: A database system providing stored procedures as web services is described. In one embodiment, for example, in a database system, a method of the present invention is described for providing a stored procedure as a Web service, the method comprises steps of: predefining a stored procedure to be invoked upon receiving a client request for a particular Web service; receiving an incoming request from a particular client for the particular Web service; in response to the incoming request, identifying the stored procedure that is predefined for the particular Web service; executing the identified stored procedure for generating a result set; and returning the result set back to the particular client.

Abstract: Compounds according formula (I) A-G-Z-W and pharmaceutically acceptable salts, solvates or hydrates thereof; wherein, A is (C6-C10)aryl, (C6-C10)aryl-SO2, (C6-C10)aryl-CH2—, (C6-C10)arylcarbonyl, (C1-C9)heteroaryl, (C1-C9)heteroaryl-SO2—, (C1-C9)heteroaryl-CH2—; or (C1-C9)heteroarylcarbonyl; G is selected from the group consisting of: where B is (C6-C10)aryl or (C1-C9)heteroaryl, and X is CH2, SO2, or carbonyl; where X is CH2, SO2, or carbonyl; and R1 and R1? are each independently selected from H, CN, (C1-C8)alkyl-, and phenyl(CH2)—, wherein said alkyl and phenyl groups are optionally substituted; and where Z and W are as defined in the present Specificiation; and pharmaceutical compositions and methods useful to increase secretion of growth hormone(GH) from the anterior pituitary of mammals, including on a sustained release basis.

Abstract: Compounds according to the formula A-Z-W as herein described, wherein A is selected from the groups consisting of: A′-(CH2)n—, A′-(CH2)nSO2—, and A′-(CH2)nCO—, where n is 0 to 4; and A═ is selected from